Skip to main content
Equibles
CERS logo

CERS · Cerus Corp

Track CERS — free

Use CERS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CERS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.98 +0.14 (+4.93%) At close · Aug 14
Market Cap
$600.54M
Shares
201.52M

Cerus Corp Earnings Call Transcripts

Every quarterly earnings call for Cerus Corp (CERS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $43.24M −$7.72M '25 Q1 25-05-01 · $52.45M −$5.71M '25 Q2 25-08-05 ▲24.1% $53.66M −$1.64M '26 Q1 26-04-30 LATEST ▲9.5% $57.44M −$2.94M '26 Q2 26-07-30
Earnings call
FY26 · Q2
2026-07-30
Cerus Corporation Second Quarter 2026 Earnings Conference Call
Confident tone U.S. ISB franchise growth EMEA / international expansion ISD / fibrinogen adoption
Revenue
$57.44M
▲ 9.5% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
Cerus Corp Q1 FY2026 Earnings Call
Confident tone IFC franchise momentum Raised full-year 2026 guidance Blood Centers of America agreement execution
Revenue
$53.66M
▲ 24.1% YoY
Diluted EPS
$-0.01
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-02
Earnings conference call (announced in 8-K)
Confident tone U.S. platelet franchise and BCA agreement EMEA and Germany opportunity IFC / pathogen-reduced cryoprecipitate
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Cerus Corp Q3 FY2025 Earnings Call
Confident tone IFC (red blood cells) business and kit model transition Path to positive non-GAAP adjusted EBITDA International / EMEA expansion
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Cerus Corp Q2 FY2025 Earnings Call
Confident tone IFC (Fibrinogen Complex) Growth INT200 Illuminator Launch Red Blood Cell CE Mark Submission (Europe)
Revenue
$52.45M
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Cerus Corp Q1 FY2025 Earnings Call
Confident tone US platelet and IFC franchise growth INT200 next-generation illumination device INTERCEPT red blood cell CE Mark submission
Revenue
$43.24M
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Cerus Corp Q4 FY2024 Earnings Call
Confident tone 2025 Revenue Guidance & Outlook International Geographic Expansion U.S. IFC (Fibrinogen Complex) Franchise
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
Cerus Corp Q3 FY2024 Earnings Call
Confident tone INTERCEPT Fibrinogen Complex (IFC) Operating Cash Flow and EBITDA Leverage BARDA Contract and RBC Program
Diluted EPS
$-0.02
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Cerus Corp Q2 FY2024 Earnings Call
Confident tone IFC (Interluekin/synthetic) franchise growth Adjusted EBITDA breakeven target International expansion (Canada, EMEA, Middle East, China)
Diluted EPS
$-0.03
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Cerus Corp Q1 FY2024 Earnings Call
Positive tone INTERCEPT Fibrinogen Complex (IFC) Cash Flow & Working Capital ReCePI Phase III RBC Trial
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
Cerus Corp Q4 FY2023 Earnings Call
Confident tone INTERCEPT Fibrinogen Complex (IFC) U.S. launch INTERCEPT platelet franchise growth First positive non-GAAP adjusted EBITDA
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Cerus Corp Q3 FY2023 Earnings Call
Diluted EPS
$-0.04
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Cerus Corp Q2 FY2023 Earnings Call
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Cerus Corp Q1 FY2023 Earnings Call
Diluted EPS
$-0.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Cerus Corp Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cerus Corp Q3 FY2022 Earnings Call
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Cerus Corp Q2 FY2022 Earnings Call
Diluted EPS
$-0.05
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Cerus Corp Q1 FY2022 Earnings Call
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-22
Cerus Corp Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Cerus Corp Q3 FY2021 Earnings Call
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Cerus Corp Q2 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
Cerus Corp Q1 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q3
2020-10-29
Cerus Corp Q3 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Cerus Corp Q2 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Cerus Corp Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts CIK 1020214 CUSIP 157085101 13F (30d) 178 filings 174 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)